Opendata, web and dolomites

OncoSeq

OncoSeq: an innovative single-cell system for immunomonitoring

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OncoSeq project word cloud

Explore the words cloud of the OncoSeq project. It provides you a very rough idea of what is the project "OncoSeq" about.

generation    seq    sequencing    sale    context    markers    plays    immunotherapies    single    ngs    cell    mass    phenotype    cancer    cells    readout    immune    capacity    fluorescence    create    output    tumor    multiplexing    prognosis    cytometer    spectrometry    transcriptome    adapt    immunity    licensing    host    validated    erc    specialising    decision    powerful    disease    creation    ultimately    stratification    immunotherapy    immuno    evoevo    marker    cytof    internal    diagnosis    central    quality    simultaneous    monitoring    industrial    tool    consumables    oncoseq    resolution    transcriptomic    transferred    follow    infiltrating    liquid    rna    quantity    flow    progression    microfluidics    vital    biopsy    oncology    infiltrate    plan    strategies    company    cytometry    thousands    tumour    circulating    patient    prototype    diagnostic    droplet    phenotypic    le    markets    entirely    clinical    instruments    site    tens    100s    barcoding    genotype    throughput    molecular    exist    prognostic    once    maps   

Project "OncoSeq" data sheet

The following table provides information about the project.

Coordinator
PARMENIDES STIFTUNG 

Organization address
address: KIRCHPLATZ 1
city: MUNCHEN
postcode: 82049
website: www.parmenides-foundation.org

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2018-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PARMENIDES STIFTUNG DE (MUNCHEN) coordinator 41˙250.00
2    ECOLE SUPERIEURE DE PHYSIQUE ET DECHIMIE INDUSTRIELLES DE LA VILLE DEPARIS FR (PARIS) participant 108˙750.00

Map

 Project objective

Host immunity plays a central and complex role in tumour progression, and the quality and quantity of immune infiltrate at the tumour site is used as a prognostic marker of cancer progression. Therefore, detailed single-cell analysis of tumor infiltrating immune cells, and ultimately liquid biopsy of circulating immune cells, is of vital importance for the development of new and improved immunotherapy strategies, and for diagnosis, prognosis, patient stratification and follow-up. We propose in OncoSeq to adapt the droplet barcoding microfluidics system, an output from the ERC EVOEVO project, to develop a novel “molecular cytometer” for high-throughput transcriptomic and phenotypic analysis, at the single-cell level, of tumor infiltrating or circulating immune cells. Readout of genotype and phenotype will be entirely based on next generation sequencing (NGS) allowing higher phenotypic multiplexing capacity (100s of phenotypic markers) than fluorescence (Flow cytometry) or mass spectrometry (CyTOF) based approaches (≤40 markers) and simultaneous RNA-sequencing (RNA-seq), allowing the creation of high-resolution phenotype-transcriptome maps for tens of thousands of single cells. This will be a powerful tool for cancer prognosis, clinical decision making and monitoring of disease progression, especially in the context of immunotherapy. So far, no such diagnostic instruments, enabling high-throughput single-cell phenotypic and transcriptomic analysis, exist. The technology developed will be transferred to our industrial partner through licensing for internal development of novel immunotherapies. In addition, once the prototype system is fully validated, we plan, with our industrial partners, to create a new company specialising in the sale of instruments and associated consumables for clinical single-cell immuno-monitoring for the research and clinical oncology markets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOSEQ" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOSEQ" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

Diverge (2019)

Generation of ultra-deep libraries of transcriptional activators for gene therapy

Read More